Tigilanol tiglate

Tigilanol tiglate (EBC-46) is a protein kinase C (PKC) /C1 domain activator. Tigilanol tiglate is associated with mitochondrial/endoplasmic reticulum (ER) dysfunction, leading to activation of the unfolded protein response (UPRmt/ER) and subsequent induction of ATP depletion, organelles expansion, Caspase activation, gasdermin E cleavage, and terminal necrosis. Tigilanol tiglate, as a small anti-tumor molecule with immunomodulatory effects, can be used in the study of head and neck squamous cell carcinoma and soft tissue sarcoma[1][2][3].

Product Specifications

CAS Number

[943001-56-7]

Product Name Alternative

EBC-46

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Caspase; PKC

Type

Natural Products

Related Pathways

Apoptosis; Epigenetics; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tigilanol-tiglate.html

Purity

95.89

Smiles

CC[C@H](C)C(O[C@@]12[C@@]([C@]3([H])[C@@]4([H])[C@](O4)([C@H]([C@]5([C@](C=C(C5=O)C)([H])[C@]3([C@@H]([C@H]2OC(/C(C)=C/C)=O)C)O)O)O)CO)([H])C1(C)C)=O

Molecular Formula

C30H42O10

Molecular Weight

562.65

Precautions

H315, H319

References & Citations

[1]Cullen J K, et al. Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade[J]. Journal for ImmunoTherapy of Cancer, 2024, 12 (4) .|[2]Miller J, et al. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors. Front Vet Sci. 2019 Apr 9;6:106.|[3]Antwi FD, et al. Tigilanol Tiglate-Induced Changes in Secretome Profiles Alter C-Met Phosphorylation and Cell Surface Protein Expression in H357 Head and Neck Cancer Cells. Cells. 2024 Jun 5;13 (11) :982.